tiprankstipranks
Trending News
More News >
Xilio Therapeutics (XLO)
NASDAQ:XLO
US Market
Advertisement

Xilio Therapeutics (XLO) Stock Statistics & Valuation Metrics

Compare
204 Followers

Total Valuation

Xilio Therapeutics has a market cap or net worth of $38.52M. The enterprise value is -$48.41M.
Market Cap$38.52M
Enterprise Value-$48.41M

Share Statistics

Xilio Therapeutics has 51,829,014 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding51,829,014
Owned by Insiders18.25%
Owned by Institutions36.92%

Financial Efficiency

Xilio Therapeutics’s return on equity (ROE) is -3.31 and return on invested capital (ROIC) is -134.62%.
Return on Equity (ROE)-3.31
Return on Assets (ROA)-0.82
Return on Invested Capital (ROIC)-134.62%
Return on Capital Employed (ROCE)-1.38
Revenue Per Employee99.13K
Profits Per Employee-910.02K
Employee Count64
Asset Turnover0.09
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Xilio Therapeutics is ―. Xilio Therapeutics’s PEG ratio is 0.01.
PE Ratio
PS Ratio8.06
PB Ratio2.90
Price to Fair Value2.90
Price to FCF-2.78
Price to Operating Cash Flow-5.75
PEG Ratio0.01

Income Statement

In the last 12 months, Xilio Therapeutics had revenue of 6.34M and earned -58.24M in profits. Earnings per share was -1.09.
Revenue6.34M
Gross Profit6.34M
Operating Income-60.58M
Pretax Income-58.24M
Net Income-58.24M
EBITDA-58.00M
Earnings Per Share (EPS)-1.09

Cash Flow

In the last 12 months, operating cash flow was -13.33M and capital expenditures -438.00K, giving a free cash flow of -13.77M billion.
Operating Cash Flow-13.33M
Free Cash Flow-13.77M
Free Cash Flow per Share-0.27

Dividends & Yields

Xilio Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta-0.17
52-Week Price Change-8.64%
50-Day Moving Average0.75
200-Day Moving Average0.79
Relative Strength Index (RSI)42.34
Average Volume (3m)763.65K

Important Dates

Xilio Therapeutics upcoming earnings date is Nov 6, 2025, Before Open (Confirmed).
Last Earnings DateAug 14, 2025
Next Earnings DateNov 6, 2025
Ex-Dividend Date

Financial Position

Xilio Therapeutics as a current ratio of 2.21, with Debt / Equity ratio of 107.03%
Current Ratio2.21
Quick Ratio2.21
Debt to Market Cap0.00
Net Debt to EBITDA0.81
Interest Coverage Ratio-605.82

Taxes

In the past 12 months, Xilio Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00

Enterprise Valuation

Xilio Therapeutics EV to EBITDA ratio is -0.07, with an EV/FCF ratio of -0.21.
EV to Sales0.62
EV to EBITDA-0.07
EV to Free Cash Flow-0.21
EV to Operating Cash Flow-0.22

Balance Sheet

Xilio Therapeutics has $121.55M in cash and marketable securities with $7.57M in debt, giving a net cash position of $113.98M billion.
Cash & Marketable Securities$121.55M
Total Debt$7.57M
Net Cash$113.98M
Net Cash Per Share$2.20
Tangible Book Value Per Share$0.33

Margins

Gross margin is 100.00%, with operating margin of -954.95%, and net profit margin of -918.05%.
Gross Margin100.00%
Operating Margin-954.95%
Pretax Margin-918.05%
Net Profit Margin-918.05%
EBITDA Margin-914.27%
EBIT Margin-940.18%

Analyst Forecast

The average price target for Xilio Therapeutics is $2.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$2.00
Price Target Upside170.27% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast536.44%
EPS Growth Forecast63.68%

Scores

Smart Score6
AI Score
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis